EU and US could reach trade deal this weekend - Reuters
On Wednesday, H.C. Wainwright adjusted its outlook on BioNTech (NASDAQ:BNTX) shares by reducing the 12-month price target from $145.00 to $134.00, while reaffirming a Buy rating on the stock. According to InvestingPro data, the stock currently trades below its Fair Value, with analyst targets ranging from $109 to $170. The revision followed BioNTech’s first-quarter financial results for 2025, which revealed net earnings per diluted share of €1.73, falling short of H.C. Wainwright’s earlier projection of €2.07 per share. The decrease in the price target is attributed to significantly lower-than-anticipated operating expenses reported by the company.
BioNTech’s revenue for the first quarter stood at €244.4 million, surpassing the analyst firm’s estimate of €186.7 million. Research and Development (R&D) expenses for the quarter were reported at €525.6 million alongside Selling, General and Administrative (SG&A) expenses of €120.6 million. These figures were lower than H.C. Wainwright’s forecasted €636.3 million for R&D and €149.1 million for SG&A expenses.
Despite these results, H.C. Wainwright anticipates a full-year net loss per diluted share of €4.99 for BioNTech in 2025, a slight increase from the previously estimated loss of €4.87 per share. The company concluded the first quarter with a robust balance sheet, holding approximately €15.9 billion in cash, cash equivalents, marketable securities, and trade receivables. InvestingPro analysis confirms this strength, highlighting that BioNTech holds more cash than debt and maintains liquid assets exceeding short-term obligations.
The research firm remains optimistic about BioNTech’s prospects. The biotechnology company’s significant financial reserves, expanding product pipeline, and the expected release of multiple sets of data in the near future are cited as reasons for the positive outlook. Despite the sharp decrease in COVID-19 vaccine-related revenues since the decline of the pandemic, H.C. Wainwright believes BioNTech continues to present a promising investment opportunity. The firm’s reiteration of the Buy rating comes with an adjusted price target, taking into account the anticipated higher operating expenses and the current cash position of the company. For deeper insights into BioNTech’s financial health and growth potential, access the comprehensive Pro Research Report available on InvestingPro, which includes detailed analysis of the company’s fundamentals and future prospects.
In other recent news, BioNTech reported first-quarter 2025 financial results, revealing revenue of €182.8 million, which fell short of the €204.08 million consensus estimate. Despite the revenue miss, the company’s loss per share was narrower than expected at €1.73, compared to the anticipated €2.00 loss per share. The company’s net loss for the quarter was €415.8 million, an increase from the €315.1 million loss in the same period last year, largely due to higher research and development expenses. BioNTech maintains a significant cash reserve of €15.9 billion, highlighting its strong financial position. The company continues to advance its oncology pipeline, with progress noted in registrational-enabling studies for its anti-PD-L1/VEGF bispecific candidate BNT327. Citi analysts have adjusted BioNTech’s stock price target to $140 from $145, while maintaining a Buy rating, reflecting confidence in the company’s prospects. The company also reaffirmed its full-year 2025 revenue guidance of €1.7 billion to €2.2 billion. BioNTech is working on a Biologics License Application for its HER2-directed ADC, expected by the end of 2025, which could diversify its revenue streams beyond COVID-19 vaccine sales.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.